Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.31, $0.58 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $87 million versus the consensus estimate of $69.37 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2024 revenue of $275-300 million, versus the consensus of $260.4 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Full Circle Lithium closes $5.14M private placement
• Phillips 66, Marathon Merger Talks Collapsed - Semafor